Generation Bio
Generation Bio is dedicated to transforming the treatment of T cell–driven autoimmune diseases through innovative siRNA therapeutics. Their proprietary cell-targeted lipid nanoparticle (ctLNP) technology enables selective delivery of siRNA to T cells, allowing for precise modulation of immune responses while sparing the broader immune system. With a focus on unlocking undruggable targets and achieving genetic precision, Generation Bio aims to develop more potent, better-tolerated treatments. Their mission is driven by a team of experienced scientists and industry leaders committed to changing what’s possible for patients with autoimmune diseases.
Industries
Nr. of Employees
medium (51-250)
Generation Bio
Cambridge, Massachusetts, United States, North America
Products
Cell-targeted lipid nanoparticle siRNA delivery platform
A modular, ligand-directed lipid nanoparticle platform engineered to deliver siRNA selectively to T cells, designed to modulate T cell function for development of therapeutics for T cell–driven autoimmune diseases.
Cell-targeted lipid nanoparticle siRNA delivery platform
A modular, ligand-directed lipid nanoparticle platform engineered to deliver siRNA selectively to T cells, designed to modulate T cell function for development of therapeutics for T cell–driven autoimmune diseases.
Expertise Areas
- RNA therapeutics (siRNA)
- Targeted nanoparticle delivery
- Lipid formulation chemistry
- Preclinical in vivo delivery and testing
Key Technologies
- siRNA therapeutics
- Lipid nanoparticle (LNP) delivery
- Ligand-directed cell targeting
- Ionizable lipid design